drugset / Trial / NCT06234631
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
Phase 2
Recruiting
380 enrolled
Chad Brummett
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedFactorialTriple-blindTreatment
Summary
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Timeline
- Start
- 2024-03-13
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 150 mg | Oral |